Outcomes of liver transplant recipients with pretransplant malignancies: Insights from a single institution’s experience. Biomarker testing and targeted therapy use among patients with non-small cell ...
Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.
Highlighting the critical role of Caris GPSai in improving cancer care. IRVING, Texas, March 20, 2026 /PRNewswire/ -- Caris ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Results from an exploratory analysis of the TROPION-Lung01 phase 3 trial showed TROP2 as measured by quantitative continuous scoring (QCS), AstraZeneca’s ...
Record CyPath® Lung Revenue and Unit Sales. Revenue from our noninvasive diagnostic for lung cancer increased 87% over 2024 with the number of tests performed rising 99% year over year, reflecting ...
InvestorsHub on MSN
BioAffinity launches large-scale clinical study for lung cancer detection technology
Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...
SAN ANTONIO, March 10, 2026--bioAffinity Technologies launches 2,000-patient longitudinal study for its CyPath Lung noninvasive diagnostic for lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results